The phase III trial in the era of targeted therapy: Unraveling the "go or no go" decision

Journal of Clinical Oncology

Volumn 21, Issue 19, 2003, Pages 3683-3695

  Roberts Jr , Thomas G ^a   Lynch Jr , Thomas J ^a   Chabner, Bruce A ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER RESEARCH; DATA BASE; EMBASE; FOOD AND DRUG ADMINISTRATION; MEDICAL LITERATURE; MEDICAL RESEARCH; MEDLINE; ONCOLOGY; PRIORITY JOURNAL; DECISION SUPPORT SYSTEM; FACTUAL DATABASE; HUMAN; METHODOLOGY; PHASE 3 CLINICAL TRIAL;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III; DATABASES, FACTUAL; DECISION SUPPORT TECHNIQUES; HUMANS; RESEARCH DESIGN;

EID: 0141973782     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.01.204     Document Type: Article

References (68)

1. Frei E III, Holland JF, Schneiderman MA, et al: A comparative study of two regimens of combination chemotherapy in acute leukemia. Blood 13:1126-1147, 1958
2. Sylvester R, Van Glabbeke M, Collette L, et al: Statistical methodology of phase III cancer clinical trials: Advances and future perspectives. Eur J Cancer 38:5162-5168, 2002 (suppl 4)
3. Simon R: Randomized clinical trials in oncology: Principles and obstacles. Cancer 74:2614-2619, 1994
4. Byar DP, Simon RM, Friedewald WT, et al: Randomized clinical trials: Perspectives on some recent ideas. N Engl J Med 295:74-80, 1976
5. Nottage M, Siu LL: Principles of clinical trial design. J Clin Oncol 20:42S-46S, 2002 (suppl)
6. Schein PS: The case for a new national program for the development of cancer therapeutics. J Clin Oncol 19:3142-3153, 2001
7. Schellens JH, Ratain MJ: Endostatin: Are the 2 years up yet? J Clin Oncol 20:3758-3760, 2002
8. Stadler WM, Ratain MJ: Development of target-based antineoplastic agents. Invest New Drugs 18:7-16, 2000
9. Gelmon KA, Eisenhauer EA, Harris AL, et al: Anticancer agents targeting signaling molecules and cancer cell environment: Challenges for drug development? J Natl Cancer Inst 91:1281-1287, 1999
10. Ratain MJ, Stadler WM: Clinical trial designs for cytostatic agents. J Clin Oncol 19:3154-3155, 2001
11. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
12. Bailar JC III, Gornik HL: Cancer undefeated. N Engl J Med 336:1569-1574, 1997
13. National Cancer Institute Physicians Query Database. http://www. cancer.gov/cancerinfo/pdq/cancerdatabase. Accessed May 13, 2003
14. ClinicalTrials.gov: A Service of the National Institutes of Health, Developed by the National Library of Medicine. http://www.clinicaltrials.gov/. Accessed May 13, 2003
15. Mathien MP: Parexel's Pharmaceutical R&D Statistical Sourcebook 2002/2003. Boston, MA; Parexel International Corporation, 2002
16. US 21 Code of Federal Regulations, Parts 314.500-314.560
17. US Food and Drug Administration, Guidance for Industry: FDA Approval of New Cancer Treatment Uses for Marketed Drugs and Biological Products (March 13, 1997). Rockville, MD, FDA guidance doc
18. Food and Drug Administration Modernization Act of 1997, Pub. L. No. 105-115, 111 Slat. 2296 (Nov. 21, 1997)
19. US Food and Drug Administration Center for Drug Evaluation and Research Oncology Tools web site.http://www.fda.gov/cder/cancer/. Accessed March 13, 2003
20. New medicines in development for cancer. Washington, DC, Pharmaceuticals Research and Manufacturers Association of America, 2001, pp 1-56
21. Hirschfeld S, Pazdur R: Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 42:137-143, 2002
22. Shulman SR, Wood-Armany MJ: Accelerating access to cancer drugs. J Biolaw Bus 2:38-44, 1999
23. Schilsky RL: End points in cancer clinical trials and the drug approval process. Clin Cancer Res 8:935-938, 2002
24. Johnson JR, Williams G, Pazdur R: End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404-1411, 2003
25. Interim analysis of phase III data preferable for accelerated approval, FDA's Pazdur says. Cancer Lett 28:1-4, 2002
26. DiMasi JA, Hansen RW, Grabowski HG: The price of innovation: New estimates of drug development costs. J Health Econ 22:151-185, 2003
27. DiMasi JA, Hansen RW, Grabowski HG, et al: Cost of innovation in the pharmaceutical industry. J Health Econ 10:107-142, 1991
28. Roche K, Paul N, Smuck B, et al: Factors affecting workload of cancer clinical trials: Results of a multicenter study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 20:545-556, 2002
29. Carter SK: Clinical strategy for the development of angiogenesis inhibitors. Oncologist 5:51-54, 2000 (suppl 1)
30. Von Hoff DD: There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clin Cancer Res 4:1079-1086, 1998
31. Dimasi JA: Risks in new drug development: Approval success rates for investigational drugs. Clin Pharmacol Ther 69:297-307, 2001
32. Tufts Center for the Study of Drug Development quantifies savings from boosting new drug R&D efficiency. Boston, MA, Tufts Center for the Study of Drug Development, September 9, 2002. http://csdd.tufts.edu/NewsEvents/ RecentNews.asp?newsid=20. Accessed November 18, 2002
33. DiMasi JA: The value of improving the productivity of the drug development process: Faster times and better decisions. Pharmacoeconomics 20:1-10, 2002 (suppl 3)
34. Wittes RE, Friedman MA: Accrual to clinical trials. J Natl Cancer Inst 80:884-885, 1988
35. Winn RJ: Obstacles to the accrual of patients to clinical trials in the community setting. Semin Oncol 21:112-117, 1994
36. Wright JR, Crooks D, Ellis PM, et al: Factors that influence the recruitment of patients to phase III studies in oncology: The perspective of the clinical research associate. Cancer 95:1584-1591, 2002
37. Viability of cancer clinical research: Patient accrual, coverage, and reimbursement-American Medical Association Council on Scientific Affairs. J Natl Cancer Inst 83:254-259, 1991
38. Simon R, Thall PF, Ellenberg SS: New designs for the selection of treatments to be tested in randomized clinical trials. Stat Med 13:417-429, 1994
39. Chen TT, Chute JP, Feigal E, et al: A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 92:1601-1607, 2000
40. Freidlin B, Breathnach OS, Johnson BE: A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 9:917-922, 2003
41. Fazzari M, Heller G, Scher HI: The phase II/III transition: Toward the proof of efficacy in cancer clinical trials. Control Clin Trials 21:360-368, 2000
42. Yao Q, Wei LJ: Play the winner for phase II/III clinical trials. Stat Med 15:2413-2423, 2455-2458, 1996
43. Scher HI, Heller G: Picking the winners in a sea of plenty. Clin Cancer Res 8:400-404, 2002
44. De Gruttola VG, Clax P, DeMets DL, et al: Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health workshop. Control Clin Trials 22:485-502, 2001
45. Rosner GL, Stadler W, Ratain MJ: Randomized discontinuation design: Application to cytostatic antineoplastic agents. J Clin Oncol 20:4478-4484, 2002
46. Carney DN: Lung cancer: Time to move on from chemotherapy. N Engl J Med 346:126-128, 2002
47. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
48. Chabner BA: The oncologic four-minute mile. Oncologist 6:230-232, 2001
49. Reddy A, Kaelin WG: Using cancer genetics to guide the selection of anticancer drug targets. Curr Opin Pharmacol 2:366-373, 2002
50. Chabner BA, Boral AL, Multani P: Translational research: Walking the bridge between idea and cure-Seventeenth Bruce F. Cain Memorial Award lecture. Cancer Res 58:4211-4216, 1998
51. Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 295:2387-2392, 2002
52. Collins JM: Pharmacology and drug development. J Natl Cancer Inst 80:790-792, 1988
53. Johnson J, Monks A, Hollingshead M, et al: Preclinical aspects of cancer drug discovery and development, in Chabner BA, Longo D (eds): Cancer Chemotherapy and Biotherapy. Philadelphia, PA, Lippincott Williams & Wilkins, 2001, pp 17-36
54. Newell DR: Pharmacologically based phase I trials in cancer chemotherapy. Hematol Oncol Clin North Am 8:257-275, 1994
55. Pazdur R: Response rates, survival, and chemotherapy trials. J Natl Cancer Inst 92:1552-1553, 2000
56. Buyse M, Thirion P, Carlson RW, et al: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis-Meta-Analysis Group in Cancer. Lancet 356:373-378, 2000
57. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
58. Warrell RP Jr, Burchenal JH: Methylglyoxal-bis(guanylhydrazone) (methyl-GAG): Current status and future prospects. J Clin Oncol 1:52-65, 1983
59. Pommier Y, Kohlhagen G, Bailly C, et al: DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309, 1996
60. Demetri GD: ET-743: The US experience in sarcomas of soft tissues. Anticancer Drugs 13:S7-S9, 2002 (suppl 1)
61. Demetri GD, Manola J, Harmon D, et al: Ecteinascidin-743 (ET-743) Induces durable responses and promising 1-year survival rates in soft tissue sarcomas (STS): Final results of phase II and pharmakokinetic studies in the U.S.A. Proc Am Soc Clin Oncol 20:352a, 2001 (abstr 1406)
62. Chabner BA: Cytotoxic agents in the era of molecular targets and genomics. Oncologist 7:34-41, 2002 (suppl 2)
63. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000
64. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000
65. Betensky RA, Louis DN, Cairncross JG: Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 20:2495-2499, 2002
66. Castro M: The simpleton's error in drug development. J Clin Oncol 20:4606-4607, 2002
67. Laetz T, Silberman G: Reimbursement policies constrain the practice of oncology. JAMA 266:2996-2999, 1991
68. Lasagna L, Frei E III: The impact of regulations, tradition, and experimental design on clinical cancer trials: Report and recommendations resulting from Washington Cancer Trials Conference. Am J Clin Oncol 19:325-329, 1996